236 related articles for article (PubMed ID: 29423501)
1. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
[TBL] [Abstract][Full Text] [Related]
2. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
Samadder NJ; Neklason DW; Boucher KM; Byrne KR; Kanth P; Samowitz W; Jones D; Tavtigian SV; Done MW; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Davis R; Topham MK; Lynch P; Strait E; McKinnon W; Burt RW; Kuwada SK
JAMA; 2016 Mar 22-29; 315(12):1266-75. PubMed ID: 27002448
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
Samadder NJ; Foster N; McMurray RP; Burke CA; Stoffel E; Kanth P; Das R; Cruz-Correa M; Vilar E; Mankaney G; Buttar N; Thirumurthi S; Turgeon DK; Sossenheimer M; Westover M; Richmond E; Umar A; Della'Zanna G; Rodriguez LM; Szabo E; Zahrieh D; Limburg PJ
Gut; 2023 Feb; 72(2):256-263. PubMed ID: 35636921
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
Delker DA; Wood AC; Snow AK; Samadder NJ; Samowitz WS; Affolter KE; Boucher KM; Pappas LM; Stijleman IJ; Kanth P; Byrne KR; Burt RW; Bernard PS; Neklason DW
Cancer Prev Res (Phila); 2018 Jan; 11(1):4-15. PubMed ID: 29109117
[TBL] [Abstract][Full Text] [Related]
6. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
[TBL] [Abstract][Full Text] [Related]
7. Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
Ulusan AM; Rajendran P; Dashwood WM; Yavuz OF; Kapoor S; Gustafson TA; Savage MI; Brown PH; Sei S; Mohammed A; Vilar E; Dashwood RH
Cancer Prev Res (Phila); 2021 Mar; 14(3):325-336. PubMed ID: 33277315
[TBL] [Abstract][Full Text] [Related]
8. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis.
Nugent KP; Farmer KC; Spigelman AD; Williams CB; Phillips RK
Br J Surg; 1993 Dec; 80(12):1618-9. PubMed ID: 8298943
[TBL] [Abstract][Full Text] [Related]
9. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac.
Keller JJ; Offerhaus GJ; Polak M; Goodman SN; Zahurak ML; Hylind LM; Hamilton SR; Giardiello FM
Gut; 1999 Dec; 45(6):822-8. PubMed ID: 10562579
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
Cruz-Correa M; Hylind LM; Romans KE; Booker SV; Giardiello FM
Gastroenterology; 2002 Mar; 122(3):641-5. PubMed ID: 11874996
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous Polyposis.
Park JJ; Kim BC; Hong SP; Seo Y; Lee HS; Park YS; Na SY; Park SC; Park J; Kim JH; Moon CM; Huh KC; Park SJ; Cheon JH; Kim WH; Kim TI
Cancer Prev Res (Phila); 2021 May; 14(5):563-572. PubMed ID: 33509804
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis.
Cruz-Correa M; Hylind LM; Marrero JH; Zahurak ML; Murray-Stewart T; Casero RA; Montgomery EA; Iacobuzio-Donahue C; Brosens LA; Offerhaus GJ; Umar A; Rodriguez LM; Giardiello FM
Gastroenterology; 2018 Sep; 155(3):668-673. PubMed ID: 29802852
[TBL] [Abstract][Full Text] [Related]
13. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis.
Pasricha PJ; Bedi A; O'Connor K; Rashid A; Akhtar AJ; Zahurak ML; Piantadosi S; Hamilton SR; Giardiello FM
Gastroenterology; 1995 Sep; 109(3):994-8. PubMed ID: 7657130
[TBL] [Abstract][Full Text] [Related]
14. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.
Giardiello FM; Hamilton SR; Krush AJ; Piantadosi S; Hylind LM; Celano P; Booker SV; Robinson CR; Offerhaus GJ
N Engl J Med; 1993 May; 328(18):1313-6. PubMed ID: 8385741
[TBL] [Abstract][Full Text] [Related]
15. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors.
Giardiello FM; Offerhaus JA; Tersmette AC; Hylind LM; Krush AJ; Brensinger JD; Booker SV; Hamilton SR
Gut; 1996 Apr; 38(4):578-81. PubMed ID: 8707091
[TBL] [Abstract][Full Text] [Related]
16. [The effects of sulindac on the pathology of colorectal remnant polyps of familial adenomatous polyposis (FAP) patients].
Li J; Lv YM; Jin Z; Cui RL
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Aug; 37(4):371-3. PubMed ID: 16086054
[TBL] [Abstract][Full Text] [Related]
17. Sulindac causes regression of rectal polyps in familial adenomatous polyposis.
Labayle D; Fischer D; Vielh P; Drouhin F; Pariente A; Bories C; Duhamel O; Trousset M; Attali P
Gastroenterology; 1991 Sep; 101(3):635-9. PubMed ID: 1650315
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer?
Tonelli F; Valanzano R; Messerini L; Ficari F
J Surg Oncol; 2000 May; 74(1):15-20. PubMed ID: 10861602
[TBL] [Abstract][Full Text] [Related]
20. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.
Ishikawa H; Wakabayashi K; Suzuki S; Mutoh M; Hirata K; Nakamura T; Takeyama I; Kawano A; Gondo N; Abe T; Tokudome S; Goto C; Matsuura N; Sakai T
Cancer Med; 2013 Feb; 2(1):50-6. PubMed ID: 24133627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
